FDA grants breakthrough status to J&J’s nipocalimab for SjD treatment
The US Food and Drug Administration (FDA) has awarded the second breakthrough therapy designation (BTD) to Johnson & Johnson's (J&J) nipocalimab…
Immunology
-
-
ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m
ALK-Abelló has acquired rights to Neffy adrenaline nasal spray in Europe and Canada, amongst other countries, from ARS Pharmaceuticals for…
-
Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets
Canadian biotech Aurinia Pharmaceuticals has announced it will be axing its workforce by 45% in a major restructuring plan aimed…
-
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
AstraZeneca and Amgen have released topline data from a Phase III trial of its inflammatory therapy, Tezspire (tezepelumab) in patients…
-
Nektar Therapeutics to sell Alabama facility to Ampersand
US-based Nektar Therapeutics has signed a definitive agreement to divest its Huntsville, Alabama manufacturing facility and associated reagent supply business…
-
Syndax agrees funding with Royalty Pharma for Niktimvo US sales
Syndax Pharmaceuticals has entered a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo (axatilimab-csfr),…
-
Psoriasis biosimilars and pricing changes herald treatment paradigm disruptions
As biosimilars continue to arrive on the psoriasis scene, wider measures to influence drug access and emerging treatment choices in…
-
GSK to acquire Chimagen’s CMG1A46 for autoimmune disease
GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell-driven autoimmune diseases, for…
-
EC approves AstraZeneca’s Fasenra for EGPA treatment
The European Commission (EC) has approved AstraZeneca's Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic…
-
Sanofi-backed Agomab raises $89m to advance fibrotic disease treatments
Agomab Therapeutics has secured $89m in Series D funding to support clinical trials of its fibrotic disease treatments, with some…
